PUBLISHER: DelveInsight | PRODUCT CODE: 1462309
PUBLISHER: DelveInsight | PRODUCT CODE: 1462309
"OZAWADE Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about OZAWADE for Obstructive sleep apnea (OSA) in the six major markets. A detailed picture of the OZAWADE for OSA in the 6MM, i.e., EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the OZAWADE for OSA. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the OZAWADE market forecast analysis for OSA in the 6MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in OSA.
OZAWADE is indicated to improve wakefulness and reduce EDS in adult patients with OSA whose sleepiness is not satisfactorily addressed by primary OSA treatment such as CPAP or those who do not tolerate this treatment. The treatment must be initiated by a physician specializing in OSA and cardiovascular risks; OSA must be re-assessed annually. OZAWADE is not a treatment for airway obstruction in patients with OSA. The primary treatment of OSA must be maintained or regularly re-proposed in patients who have not tolerated the primary treatment.
In January 2023, Aculys Pharma initiated a Phase III trial of Pitolisant treating patients with EDS associated with OSA in Japan.
Dosage
OZAWADE should be used at the lowest effective dose based on clinical response and patient tolerance. The optimal therapeutic dose must be reached in stages, without exceeding the dose of 18 mg/day:
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
OZAWADE Analytical Perspective by DelveInsight
This report provides a detailed market assessment of OZAWADE for Obstructive sleep apnea (OSA) in the six major markets, i.e., EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
The report provides the clinical trials information of OZAWADE for OSA covering trial interventions, trial conditions, trial status, start and completion dates.